Not a good buy right now for an impatient entry: short-term momentum is weakening (MACD bearish/expanding) and the stock is trading below the key pivot (23.936).
Longer-term trend is constructive (SMA_5 > SMA_20 > SMA_200) and fundamentals/analyst stance are strong, but the current tape suggests better prices may appear near/under support.
Best stance now: hold off until price reclaims ~23.94 (pivot) with improving momentum, or it cleanly holds the 22.64 support and turns up.
Technical Analysis
Trend: Longer-term bullish structure (SMA_5 > SMA_20 > SMA_200), indicating the broader uptrend is intact.
Momentum: MACD histogram -0.282 and negatively expanding -> bearish momentum building in the near term.
RSI(6): 40.824 (neutral-to-soft) -> not oversold; no strong rebound signal yet.
Levels: Price 22.93 is below Pivot 23.936; nearest support S1 22.638 (then S2 21.836). Resistance levels R1 25.234 and R2 26.036.
Pattern-based forward read: Similar-pattern stats imply slight downside bias (next day ~-0.48%, next month ~-0.88%).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Put/Call OI ratio 0.02 (calls dominate) -> bullish positioning skew.
Activity: Reported option volume is essentially zero today -> sentiment read is limited by low liquidity/participation.
Volatility: IV (30d) 145.74 with IV percentile 87.34 -> very elevated; market is pricing large moves (often makes outright call buying expensive).
Technical Summary
Sell
5
Buy
8
Positive Catalysts
Regulatory/label-expansion momentum referenced by analysts (FDA-related expansions and accelerated protocols), supporting ongoing adoption narrative.
Analyst price targets have been repeatedly raised into the $30 area, reinforcing Street confidence.
Strong recent operating trajectory (revenue growth and profitability improvements in latest reported quarter).
Neutral/Negative Catalysts
Options signal is skewed bullish, but near-zero volume reduces reliability of that sentiment read.
Key updates: Northland raised PT to $30 (from $23) with Outperform; H.C. Wainwright raised PT to $30 (from $24) with Buy; other prior raises to $24, $23, $19, $18.
Wall Street pros: Regulatory wins/label expansions, protocol innovation, partnerships, and strengthening fundamentals.
Wall Street cons: Near-term timing risk (momentum currently soft) and less visibility on immediate catalysts given no fresh news this week.
Ownership/trading sentiment: Hedge funds neutral last quarter; insiders neutral last month.
Politicians/Congress: No recent congress trading data available; no politician activity provided.
Wall Street analysts forecast BWAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BWAY is 22 USD with a low forecast of 19 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast BWAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BWAY is 22 USD with a low forecast of 19 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.930
Low
19
Averages
22
High
24
Current: 20.930
Low
19
Averages
22
High
24
H.C. Wainwright
H.C. Wainwright
maintain
$24 -> $30
AI Analysis
2026-01-26
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$24 -> $30
AI Analysis
2026-01-26
maintain
Reason
H.C. Wainwright raised the firm's price target on Brainsway to $30 from $24 and keeps a Buy rating on the shares. The company recently announced premarket approval receipt for Neurolief's Proliv RX system, a class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder who have failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in the clinic, the analyst tells investors in a research note.
Northland
Outperform
maintain
$23 -> $30
2026-01-22
Reason
Northland
Price Target
$23 -> $30
2026-01-22
maintain
Outperform
Reason
Northland raised the firm's price target on Brainsway to $30 from $23 and keeps an Outperform rating on the shares. The firm believes that its FDA-approved SWIFT accelerated protocol and its strategic partnerships will boost both near and long-term prospects, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BWAY
